我武生物
(300357)
| 流通市值：96.60亿 | | | 总市值：104.19亿 |
| 流通股本：4.85亿 | | | 总股本：5.24亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 514,164,898.85 | 252,840,950.04 | 1,062,404,471.43 | 853,360,357.81 |
| 营业收入 | 514,164,898.85 | 252,840,950.04 | 1,062,404,471.43 | 853,360,357.81 |
| 二、营业总成本 | 303,034,492.56 | 149,929,001.8 | 635,510,347.27 | 459,695,071.95 |
| 营业成本 | 24,202,989.33 | 12,021,601.28 | 50,582,171.21 | 39,475,057.42 |
| 税金及附加 | 4,170,985.54 | 362,195.73 | 11,560,988.02 | 5,096,763.82 |
| 销售费用 | 193,571,064.95 | 95,348,070.74 | 397,842,380.84 | 291,557,577.22 |
| 管理费用 | 41,910,061.32 | 21,737,745.42 | 81,262,692.08 | 58,760,176.47 |
| 研发费用 | 47,902,156.37 | 24,912,558.24 | 117,102,467.92 | 85,698,742.52 |
| 财务费用 | -8,722,764.95 | -4,453,169.61 | -22,840,352.8 | -20,893,245.5 |
| 其中:利息费用 | 405,475.73 | 233,077.05 | 792,851.32 | 596,368.52 |
| 其中:利息收入 | 9,174,690.75 | 4,710,727.62 | 23,724,510.41 | 21,562,143.29 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,312,651.67 | 1,746,318.99 | 3,425,972.25 | 1,629,261.04 |
| 加:投资收益 | 29,032,597.07 | 29,682,739.53 | 2,721,381.62 | 212,085.8 |
| 资产处置收益 | - | - | 630,073.33 | 630,073.33 |
| 资产减值损失(新) | - | - | -4,768,382.16 | - |
| 信用减值损失(新) | -3,372,352.37 | -4,232,680.59 | -843,065.04 | -6,005,806.45 |
| 其他收益 | 4,010,664.55 | 2,984,743.78 | 10,357,356.85 | 7,566,395.89 |
| 四、营业利润 | 244,113,967.21 | 133,093,069.95 | 438,417,461.01 | 397,697,295.47 |
| 加:营业外收入 | 502,908.65 | 359,377.55 | 174,714.09 | 91,860.98 |
| 减:营业外支出 | 4,176,651.87 | 1,669,140.86 | 5,886,800.1 | 3,510,803.68 |
| 五、利润总额 | 240,440,223.99 | 131,783,306.64 | 432,705,375 | 394,278,352.77 |
| 减:所得税费用 | 31,863,303.6 | 15,270,671.79 | 64,616,129.11 | 59,041,362.8 |
| 六、净利润 | 208,576,920.39 | 116,512,634.85 | 368,089,245.89 | 335,236,989.97 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 208,576,920.39 | 116,512,634.85 | 368,089,245.89 | 335,236,989.97 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 213,451,780.13 | 119,232,154.49 | 380,940,984.34 | 344,866,533.27 |
| 少数股东损益 | -4,874,859.74 | -2,719,519.64 | -12,851,738.45 | -9,629,543.3 |
| 扣除非经常损益后的净利润 | 183,034,313.47 | 89,346,226.01 | 374,199,121.5 | 340,017,792.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.41 | 0.23 | 0.73 | 0.66 |
| (二)稀释每股收益 | 0.41 | 0.23 | 0.73 | 0.66 |
| 八、其他综合收益 | -10,367.96 | -6,064.56 | -6,986.28 | -4,046.55 |
| 归属于母公司股东的其他综合收益 | -10,367.96 | -6,064.56 | -6,986.28 | -4,046.55 |
| 九、综合收益总额 | 208,566,552.43 | 116,506,570.29 | 368,082,259.61 | 335,232,943.42 |
| 归属于母公司股东的综合收益总额 | 213,441,412.17 | 119,226,089.93 | 380,933,998.06 | 344,862,486.72 |
| 归属于少数股东的综合收益总额 | -4,874,859.74 | -2,719,519.64 | -12,851,738.45 | -9,629,543.3 |
| 公告日期 | 2026-08-28 | 2026-04-24 | 2026-04-24 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |